Accord

Accord Successfully launched Bendamustine in Ireland

We are delighted to inform that Accord Ireland have successfully launched Bendamustine. Bendamustine is an alkylating antitumour agent. Bendamustine has recorded sales of about 180Mn USD in 2014. This product launch will bring an affordable treatment option for patients and will help to reduce healthcare spending.

ACCORD Launched “TRECTYL” (Sildenafil) Tablets in Mexico.

ACCORD launched TRECTYL, Sildenafil 100mg whit 4 & 8 tablets a generic version of Viagra®. TRECTYL is indicate to treat men who have erectile dysfunction.

ACCORD Launched “LPSYRID” (Levetiracetam) Tablets in Mexico

ACCORD launched LPSYRID, Levetiracetam 500mg & 1g a generic version of Keppra. LPSYRID is used to control certain types of seizures in the treatment of epilepsy.

Accord Launched AccofilTM (filgrastim) in Europe.

We are immensely happy to announce the launch of AccofilTM

AccofilTM is biosimilar to Amgen’s Neupogen® with same range of indications.

The product will be available pre-filled syringes in two strengths i.e. 30MU/0.5ml and 48MU/0.5ml and are available in packs of one or five syringes.

Accord’s biosimilar version would offer patients comparable quality, safety and efficacy combined with cost-effectiveness.

With the launch of AccofilTM, we have successfully achieved a new milestone and added new chapter in success saga of Accord.

ACCORD Launched “NIMAN” (Temozolomide) Capsules in Mexico.

ACCORD launched NIMAN, Temozolomide 100 mg a generic version of Temodal®. The product has been launched at market formation in Mexico. NIMAN is a second generic medicine in the Mexican market. It has a price below the competition. The NIMAN launch was in the SMeO, organizated by Mexican Society of Oncology.

ACCORD Launched “SKEMCA” (Capecitabine) Tables in Mexico.

ACCORD launched SKEMCA, Capecitabine 500 mg a generic version of Xeloda®. The product has been launched at market formation in Mexico. SKEMCA is a first generic medicine in the Mexican market. It has a price below the competition. The SKEMCA launch was in the SMeO, organizated by Mexican Society of Oncology.

ACCORD launched “Traxacord” (Metotrexato) injection in Mexico.

ACCORD launched Metotrexato injection TRAXACORD in 50MG/2ml and 500 MG/5ml strengths in Mexico. Traxacord is a generic version of Ledertrexate from Pfizer.

Traxacord is used in the treatment of Neoplasms. Metrotexato is the principal inhibitor of dihydrofolate reductase enzyme.

ACCORD launched ‘‘Adptor” (Esomeprazole) Injection in Mexico.

ACCORD launched Adptor Lyophilized Injection in 40 mg strength in Mexico. Adptor is a generic version of Nexium® from Astra Zeneca.

Adptor is used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome.

Esomeprazole is a proton pump inhibitor . Esomeprazole provides improved efficacy, in terms of stomach acid control, over the R enantiomer of omeprazole.

Accord launches Capecitabine tablets in Europe

At patent expiry of Xeloda®, Capecitabine Accord will be launched in different European countries such as Sweden, Ireland, Portugal, UK, Netherlands, Germany, France, Italy, Spain, Austria, Denmark and Belgium. More European countries, 23 in total, are expected to launch the product in the coming weeks as patents expire.

Capecitabine Accord is indicated for the treatment of metastatic breast cancer, gastric and colorectal cancer and is available in tablets of 150mg, 300mg and 500mg. The new presentation of 300mg improves treatment compliance by reducing the number of tablets patient has to intake.

Capecitabine Accord is also available in cross-perforated blisters allowing for individual products to be removed from the main body of the blister without compromising the product, becoming more convenient for patients and hospital staff. This product launch will bring a more affordable treatment option for patients and will contribute to holding down the growth rate of healthcare spending.

Sildenafil film coated Tablets Launched in Europe

ACCORD launched ‘‘Sildenafil film coated 25mg, 50mg & 100mg Tablets’’, a generic version of Viagra®on the first day of patent expiry in major EU markets. Product has been launched at market formation in Italy and UK. Other European countries are expected to launch in the coming weeks.

“Sildenafil Accord” Tablet is Blue, almond shaped generic version of Viagra® from Pfizer and available in blister packs of 2, 4, 8 or 12 tablets.

Sildenafil tablets belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping to relax the blood vessels in penis, allowing blood to flow into the penis when man gets sexually excited. Sildenafil tablets are used to treat men with erectile dysfunction.

Accord strengthens its anticancer basket with the launch of Topotecan Inj. In US

Expanding its oncological offering, Accord has successfully launched Topotecan Inj. in the US market. Topotecan Hydrochloride for Injection is a topoisomerase inhibitor indicated for small cell lung cancer sensitive disease after failure of first-line chemotherapy. It is also used in combination therapy with Cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.